Lantheus (NASDAQ:LNTH) Shares Gap Down – Time to Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $114.96, but opened at $97.86. Lantheus shares last traded at $95.30, with a volume of 573,111 shares changing hands.

Analyst Ratings Changes

LNTH has been the topic of several recent research reports. JMP Securities dropped their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. B. Riley increased their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Truist Financial lowered their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Finally, Leerink Partners boosted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Stock Performance

The company’s 50-day moving average is $108.41 and its two-hundred day moving average is $95.60. The company has a market capitalization of $6.33 billion, a P/E ratio of 14.95 and a beta of 0.51. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Insiders Place Their Bets

In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently made changes to their positions in the business. Signaturefd LLC lifted its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock valued at $1,834,000 after acquiring an additional 100 shares during the last quarter. UMB Bank n.a. boosted its holdings in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the period. GAMMA Investing LLC grew its position in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after acquiring an additional 146 shares during the last quarter. Finally, Moody National Bank Trust Division increased its stake in Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after purchasing an additional 162 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.